LP352-202 A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

NCT05626634

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

Principal Investigator

Sponsor

Longboard Pharmaceuticals

You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have completed study LP352-201. LP352 is being studied to see if it might reduce the number of seizures in patients with DEE. LP352 is thought to work by activating specific sites in the brain that are associated with seizure disorders. The main goal of this study is to learn how safe different doses of LP352 are when taken for a longer period of time.